Skip to Content

The problem, the consequences, and rapid testing solutions

Healthcare Associated Infections (HAIs) are a global concern causing significant mortality and morbidity as well as spiralling healthcare costs worldwide.

Clostridium difficile is the most common cause of Healthcare Associated Diarrhea in industrialized countries.1 In North America, C. difficile is present in 13 of every 1,000 hospital inpatients2 and the estimated annual economic burden is approximately $3.2 billion.3

The Problem

Clostridium difficile infection (CDI) is commonly associated with prior exposure to broad-spectrum antibiotics that compromise a patient's normal gut flora, allowing C. difficile to proliferate and cause toxin-mediated disease. This can proceed to serious, life-threatening conditions such as Pseudomembranous Colitis (PMC).

Clostridium difficile

The Consequences

(CDI) is a consequence of antibiotic use, which is exacerbated by inappropriate and widespread use of broad-spectrum agents. Any steps which can be implemented to effectively target narrow-spectrum antibiotic therapy would have a positive impact on the down-stream incidence of (CDI) as well as a substantial reduction of associated healthcare costs. 

In addition, diagnostics for (CDI) are challenging. In recent times, traditional toxin A/B EIA tests have been identified as sub-optimal in performance and not recommended as single-line tests by various national guidelines.1,4,5,6,7

More recently, molecular-based tests have become commercially available but the latest data suggests these tests are not specific enough to be used as single-line tests.8

There are real concerns that these tests may overdiagnose (CDI), resulting in inappropriate antimicrobial therapy and an increased likelihood of a more severe re-infection.

Rapid Testing

The latest guidelines recommend an algorithmic testing approach where Glutamate Dehydrogenase (GDH) tests or molecular technology are used to screen patients and a sensitive Toxin A/B test is used to confirm disease.8


The unique C. DIFF QUIK CHEK COMPLETE®test from Alere (developed and manufactured by TechLab® Inc.) detects GDH and Toxin A/B simultaneously in less than 30 minutes. This test has been shown by multiple peer-reviewed studies from N. America, Europe and Asia to be an extremely effective tool to detect (CDI).8,9,10,11,12,13,14

Download the C. DIFF QUIK CHEK COMPLETE® Brochure

Explore Related Content and Videos

C. difficile is a global health problem

Find out why quickly and accurately determining presence of C. difficle infection is important.

C. difficile Patient Pathway

Which pathway would you choose for you patient?


Diagnostic Testing for C. difficile and Nosocomial Diarrhea: Where are we now?